Finerenone in kidney transplantation: an underinvestigated agent: review of available evidence, existing gaps, and future directions.

The study demonstrated a nonsignificant trend toward reduced tubulointerstitial fibrosis (P=0.06) in the eplerenone group but failed to show significant changes in albuminuria, blood pressure, or estimated GFR (eGFR).

also in 5,406 other papers

Finerenone reduced the risk of heart failure hospitalization by 20% and all-cause mortality by 14%, though reductions in cardiovascular death and renal failure did not reach statistical significance.

also in 111,027 other papers